Kintara Therapeutics Announces Three Abstracts Have Been Accepted for the 2022 Society for Neuro-Oncology Annual Meeting

On September 8, 2022 Kintara Therapeutics, Inc.(Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, reported that three posters have been accepted for data presentation at the 2022 Society for Neuro-Oncology (SNO) Annual Meeting (Press release, Kintara Therapeutics, SEP 8, 2022, View Source [SID1234619234]). The 2022 SNO Annual Meeting will be held from November 16 through November 20, 2022 in Tampa, Florida.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Data Presentations:

Phase 2 Study of VAL-083 and Radiotherapy in Newly-Diagnosed, MGMT-unmethylated GBM
Poster Presenter: Zhongping Chen, MD, Ph.D. – Sun Yat-sen University Cancer Center
(Presentation Time: Friday, November 18, 2022 – 7:30 to 9:30 pm ET)

Recurrent RELA Fusion-Positive Ependymoma Treated with VAL-083 under Expanded Access: A Case Report
Poster Presenter: Carlos Kamiya-Matsuoka, MD – MD Anderson Cancer Center
(Presentation Time: Friday, November 18, 2022 – 7:30 to 9:30 pm ET)

VAL-083 in Patients with Recurrent Glioblastoma Treated under Expanded Access Program
Poster Presenter: Carlos Kamiya-Matsuoka, MD – MD Anderson Cancer Center
(Presentation Time: Friday, November 18, 2022 – 7:30 to 9:30 pm ET)

Hepion Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

On September 8, 2022 Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis ("NASH"), hepatocellular carcinoma ("HCC"), and other chronic liver diseases, reported that it will participate in the H.C. Wainwright 24th Annual Global Investment Conference (Press release, Hepion Pharmaceuticals, SEP 8, 2022, https://hepionpharma.com/news/hepion-pharmaceuticals-to-participate-in-the-h-c-wainwright-24th-annual-global-investment-conference/ [SID1234619233]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Hepion’s pre-recorded presentation will be available on demand during the event for all registered attendees. Beginning on Monday, September 12, 2022, the presentation will also be available on the Company’s website at www.hepionpharma.com under "Events" in the "Investors" section.

Medable Selected by GSK to Power Decentralized and Hybrid Clinical Trials Across Global Product Portfolio

On September 8, 2022 Medable Inc., the leading software provider for patient-centered clinical trials, reported that it has entered a four-year enterprise contract with GSK to enable decentralized clinical trials (DCTs) across their portfolio using the company’s industry-leading DCT platform (Press release, Medable, SEP 8, 2022, View Source [SID1234619232]). Medable was selected by GSK to accelerate the delivery of new medicines and enable their clinical trials to be more inclusive and representative of all patient populations.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Medable’s technology was chosen after a rigorous evaluation of the leading clinical trial platforms, as it best aligns with GSK’s goals of increasing access to research, improving diversity, and creating more patient-centric trial designs. Medable’s end-to-end DCT platform provides many critical digital capabilities, including eConsent, TeleVisit, and eCOA, as well as the flexibility to deploy modern, patient-centered clinical trials.

"It is an honor to be selected by GSK as its preferred partner for decentralized clinical trials," said Dr. Michelle Longmire, Co-founder and CEO of Medable. "GSK has been a leader in innovative science for decades and is taking yet another transformational step forward by leveraging a modern, patient-centric model to conduct clinical trials with Medable. It’s incredibly exciting, and we are looking forward to helping millions of patients together."

Medable has deployed its software-as-a-service platform via more than 300 decentralized and hybrid clinical trials in 60 countries, serving more than one million patients and research participants globally. Medable’s customers have achieved impressive results with decentralized and hybrid trials – including 200 percent faster enrollment and 50 percent cost reductions. A recent 2022 financial modeling of DCTs using industry benchmark and Medable data conducted by the Tufts Center for the Study of Drug Development shows that, on average, decentralized trials can achieve net financial benefits ranging from five to 13 times for Phase II and Phase III trials, due to reduced trial timelines and other factors.

Learn more about Medable’s partnership with GSK and other life science leaders at the 12th annual DPharm Disruptive Innovations U.S. conference (Sept 13-14, 2022) in Boston – booth #48.

Cardinal Health Announces Pharmaceutical Segment Organizational Changes

On September 8, 2022 Cardinal Health (NYSE: CAH) reported Debbie Weitzman, current President of Pharmaceutical Distribution, will become CEO of the Company’s Pharmaceutical Segment (Press release, Cardinal Health, SEP 8, 2022, View Source [SID1234619231]). Weitzman will replace Victor Crawford, who will be stepping down as Pharmaceutical Segment CEO effective September 19, but will remain with the company until November 13 to help with the transition. The role of President of Pharmaceutical Distribution will be eliminated.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The company has further streamlined the Pharmaceutical Segment by restructuring and eliminating additional roles. As a result of these changes, the Pharmaceutical and Specialty Distribution businesses will both report directly to Debbie Weitzman.

"Debbie has been a tremendous leader at Cardinal Health, and we believe her knowledge and experience make her the right person to lead our redesigned Pharmaceutical Segment," said Jason Hollar, Chief Executive Officer of Cardinal Health. "I believe this new design will allow us to have added focus on specialty distribution, which is a key growth area for the company, as well as simplify how our customers and manufacturers work with us."

Hollar added, "On behalf of the Board and entire company, I want to thank Victor for his leadership and many contributions to our business and culture during his time with Cardinal Health. Victor’s steadfast leadership helped our Pharmaceutical Segment navigate the challenging environment during the pandemic, and we’re grateful he will remain with us through November 13 to ensure a smooth transition."

The moves in the Pharmaceutical Segment come as part of the company’s broader simplification efforts to streamline its organizational structure and are specifically aimed to strengthen the company’s Pharmaceutical and Specialty Distribution, as well as bring together similar services under one team.

About Debbie Weitzman
Debbie Weitzman has been President of Pharmaceutical Distribution at Cardinal Health since 2017, leading the company’s distribution efforts to thousands of pharmacies across the care continuum, from retail and hospital pharmacies to long-term care and community health center pharmacies. Debbie also led the launch of and oversees Outcomes, a unified ecosystem that brings together patient engagement, clinical intervention and pharmacy workflow solutions to enhance patient outcomes.

Throughout her 16-year career at Cardinal Health, Debbie has served in varying leadership roles across sales and distribution operations. Debbie has extensive international experience having previously served as the senior vice president and general manager of Cardinal Health Puerto Rico, responsible for sales and distribution operations for pharmaceutical products, medical-surgical products, hospital pharmacy management and logistics services in Puerto Rico and Latin America.

Prior to joining Cardinal Health, Debbie held positions of increasing responsibility at Johnson & Johnson Medical Caribbean. She began her career in banking at J.P. Morgan, followed by various marketing roles in consumer brand management both in the United States and Puerto Rico.

Debbie serves on the Board of Directors for the National Association of Chain Drug Stores, and is a delegate with the National Association of Wholesalers. She earned her bachelor’s degree in history from Dartmouth College and a master’s degree from Kellogg Graduate School of Management at Northwestern University.

Actinium Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

On September 8, 2022 Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company) a leader in the development of targeted radiotherapies for patients with unmet needs, reported that it will be participating in the H.C. Wainwright 24th Annual Global Investment Conference, being held September 12-14, 2022 (Press release, Actinium Pharmaceuticals, SEP 8, 2022, https://ir.actiniumpharma.com/news/detail/422/actinium-pharmaceuticals-to-participate-in-the-h-c-wainwright-24th-annual-global-investment-conference [SID1234619230]). The conference will be hybrid and occur virtually and in person at the Lotte New York Palace Hotel in New York City.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Members of Actinium’s management team will conduct one-on-one meetings. Please contact your representative at H.C. Wainwright to schedule a one-on-one meeting with the Actinium management team. For information about the H.C. Wainwright Global Investment Conference, please refer to the event’s website. Actinium’s investor presentation will be available on the conference website as well the investor relations page of the Company’s website at www.actiniumpharma.com/presentations-webinars.